Antigen-specific downregulation of T cells by doxorubicin delivered through a recombinant MHC II–peptide chimera

Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor

1996 • 1,946 citations

Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II

1984 • 1,477 citations

The Th1/Th2 paradigm

1997 • 1,102 citations

Adriamycin

1974 • 1,051 citations

Kinetics of T-cell receptor binding to peptide/I-Ek complexes: correlation of the dissociation rate with T-cell responsiveness.

1994 • 431 citations

High- and Low-Potency Ligands with Similar Affinities for the TCR

1998 • 322 citations

Ligand-specific oligomerization of T-cell receptor molecules

1997 • 232 citations

Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor

1992 • 221 citations

Antigen Analogs/MHC Complexes as Specific T Cell Receptor Antagonists

1994 • 195 citations

MHC interaction and T cell recognition of carbohydrates and glycopeptides.

1992 • 171 citations

Immunosuppressive agents in organ transplantation: past, present, and future.

2000 • 145 citations

The role of membranes in the mechanism of action of the antineoplastic agent adriamycin. Spin-labeling studies with chronically hypoxic and drug-resistant tumor cells.

1983 • 139 citations

A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers

1978 • 126 citations

Cell surface actions of adriamycin

1991 • 109 citations

Tolerance and Immunity in the Intestinal Immune System

2000 • 77 citations

Doxorubicin-induced cell death in highly invasive human gliomas.

1999 • 69 citations

Kinetics of T-cell Receptor Binding by Bivalent HLA-DR·Peptide Complexes That Activate Antigen-specific Human T-cells

2000 • 68 citations

Antigen-Specific Signaling by a Soluble, Dimeric Peptide/Major Histocompatibility Complex Class II/Fc Chimera Leading to T Helper Cell Type 2 Differentiation

1999 • 63 citations

Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen.

1999 • 55 citations

Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis

2000 • 49 citations

Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II: Acetylcholine receptor peptide complexes

1995 • 42 citations

Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells

2000 • 32 citations

Engineering and characterization of a murine MHC class II- immunoglobulin chimera expressing an immunodominant CD4 T viral epitope

1997 • 29 citations

Decreased CP-1 (NF-Y) Activity Results in Transcriptional Down-Regulation of Topoisomerase IIα in a Doxorubicin-Resistant Variant of Human Multiple Myeloma RPMI 8226

1997 • 23 citations

Prevalence of human papilloma virus DNA in head and neck cancers carrying wild-type or mutant p53 tumor suppressor genes.

1999 • 20 citations

Interaction of calicheamicin γ ₁ ^I and its related carbohydrates with DNA–protein complexes

1999 • 18 citations

Enzymatically mediated, glycosidic conjugation of immunoglobulins with viral epitopes

1995 • 15 citations

Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors

1995 • 13 citations

Antigen-specific deletion of cloned T cells using peptide-toxin conjugate complexed with purified class II major histocompatibility complex antigen.

1994 • 10 citations

Induction of class II major histocompatibility complex blockade as well as T cell tolerance by peptides administered in soluble form

1996 • 3 citations